10x Genomics (TXG) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

$0.03

Estimate

-$0.02

Surprise

+240.3%

Score at report (before → after)

4.6 → 4.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

10x Genomics (TXG) beat the -$0.02 estimate with adjusted EPS of $0.03 — a large 240.3% upside surprise. TrendMatrix's engine moved from Hold (4.6/10) to Sell at 4.5/10 after the report — the engine's score fell despite the beat.

• UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $61 — benzinga, 2026-11-06
• Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $60 — benzinga, 2026-11-06
• Analysts Update Price Targets for 10x Genomics Following Q3 Earnings — fiscal.ai, 2026-11-06

TrendMatrix currently rates TXG Sell at 4.8/10.

4 of the last 4 quarters beat the estimate; this quarter's +240.3% surprise compares with a +248.5% four-quarter average. Next scheduled report: 2027-02-11.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$59.28

Price target

$67.42

Stop

$55.13

Upside to target

+13.7%

Reward-to-risk

0.9:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Devices

Market cap

$7.72B

P/E (fwd)

773.2

52-week range

$13.58–$102.81

Off 52-week high

42.3%

RSI (14)

42

Volume vs avg

1.26×

Score today

4.8/10